Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,289 across all filing types
Latest filing 2024-04-18 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物外汇套期保值业务管理制度（2024年4月制定）
Governance Information Classification · 95% confidence The document is titled '郑州安图生物工程股份有限公司 外汇套期保值业务管理制度' which translates to 'Zhengzhou Antu Bioengineering Co., Ltd. Foreign Exchange Hedging Business Management System'. It is a detailed internal policy document outlining the principles, approval authority, management, operational procedures, risk handling, and disclosure requirements related to the company's foreign exchange hedging activities. It references compliance with laws and stock exchange rules but does not contain financial statements, earnings data, or audit results. It is not an announcement or a report of financial results but a governance and operational policy document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-04-18 Chinese
安图生物关于调整第四届董事会审计委员会成员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the adjustment of members of the audit committee of the company's fourth board of directors. It details changes in board committee membership, specifically the audit committee, and references compliance with relevant regulations. There is no financial data, no report attached or referenced as being published, and no mention of a meeting or voting results. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2024-04-18 Chinese
安图生物2023年度募集资金存放和实际使用专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年度募集资金存放和实际使用专项报告" which translates to "2023 Annual Report on the Storage and Actual Use of Raised Funds." It details the management, storage, and usage of funds raised through convertible bonds and non-public stock issuance, including detailed financial figures, investment projects, and compliance with regulatory requirements. It also includes auditor and sponsor institution verification reports on the use of raised funds. The document is comprehensive, contains substantive financial data, and focuses specifically on the use and management of raised capital. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not a general annual report (10-K), nor a simple announcement or certification. Therefore, the correct classification is CAP with high confidence.
2024-04-18 Chinese
安图生物2024年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 年第一季度报告' which translates to '2024 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on non-recurring items. The report covers the period of the first quarter of 2024 and includes unaudited financial statements. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is over 13,000 characters, indicating it is the full report, not just an announcement or summary. Therefore, the appropriate classification is 'IR' for Interim / Quarterly Report.
2024-04-18 Chinese
安图生物关于以集中竞价交易方式回购公司股份比例达1%暨回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount paid, and the status of two repurchase plans. The document references compliance with relevant regulations and provides specific dates and figures related to the share buyback. It does not contain financial statements or detailed financial analysis but focuses on the update of the company's own share transactions. This matches the description of a 'Transaction in Own Shares' filing, which reports on the company's buyback or sale of its own shares.
2024-04-08 Chinese
安图生物关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of its share repurchase program through centralized bidding transactions. It details the number of shares repurchased, prices, total amounts paid, and compliance with relevant regulations. The document is short (1031 characters) and focuses on the progress of a share buyback, not a full financial report or earnings release. It matches the description of a 'Transaction in Own Shares' filing, which reports on the company's buyback or sale of its own shares.
2024-04-01 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.